Quarterly report [Sections 13 or 15(d)]

Segment Information - Schedule of financial information regularly reviewed and used by the CODM (Details)

v3.25.2
Segment Information - Schedule of financial information regularly reviewed and used by the CODM (Details) - USD ($)
 3 Months Ended 6 Months Ended
Feb. 21, 2025
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Research and development (excluding stock-based compensation) expense:              
PAH   $ 2,738,794   $ 0   $ 12,069,638 [1] $ 0 [1]
Parkinson's disease   42,196   2,666,108   184,616 5,010,004
Other programs   834,142   417,428   1,421,270 806,881
Selling, general and administrative (excluding stock-based compensation)   3,366,824   1,936,302   7,027,106 3,931,879
Change in fair value contingent consideration $ 4,435,443 (358,420)   0   (1,523,284) 0
Stock-based compensation expense   4,208,742   30,697   6,250,938 84,131
Total costs and expenses   10,832,278   5,050,535   25,430,284 9,832,895
Loss from operations   (10,832,278)   (5,050,535)   (25,430,284) (9,832,895)
Interest income   916,755   90,927   1,836,026 223,652
Net loss   (9,915,523) $ (13,678,735) (4,959,608) $ (4,649,635) (23,594,258) (9,609,243)
Operating Segment              
Research and development (excluding stock-based compensation) expense:              
Stock-based compensation expense   $ 4,208,742   $ 30,697   $ 6,250,938 $ 84,131
[1] This amount includes a one-time (non-cash) charge of $7.4 million for the acquired IPR&D related to the CorHepta acquisition.